ArticleNature communications2026
Linoleic acid accelerates osteoarthritis progression in male rats by targeting iron-sulfur clusters to drive ferroptosis in chondrocytes.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of osteoarthritis (OA) is accompanied by various metabolic disorders, highlighting the need for further investigation into metabolism-related pathogenesis and targeted therapeutic strategies. Herein, we found that linoleic acid (LA), the most abundant essential fatty acid in the diet, accumulates in the blood, synovial fluid, and cartilage tissue of elderly and OA individuals. Notably, LA not only induces ferroptosis in chondrocytes, but it also serves as a risk metabolite, driving OA onset and accelerating the progression of traumatic OA in male rat models. Mechanistically, LA can directly bind to iron-sulfur cluster assembly enzyme (ISCU) to induce its autophagic degradation and inhibit iron-sulfur cluster synthesis, which subsequently activates IRP1-mediated translational regulation to drive the ferroptosis process. Furthermore, upregulating or supplementing ISCU in cartilage tissue contributes to mitigating LA accumulation and trauma-induced OA progression, and this strategy can further enhance the therapeutic efficacy of moderate exercise in OA treatment by effectively inhibiting ferroptosis. Taken together, our findings identify LA as a key metabolite involved in the onset and progression of OA by driving ferroptosis and propose a targeted therapeutic strategy based on ISCU supplementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.